Global Resistance of Imipenem/Relebactam against Gram-Negative Bacilli: Systematic Review and Meta-Analysis.
Curr Ther Res Clin Exp
; 100: 100723, 2024.
Article
em En
| MEDLINE
| ID: mdl-38174096
ABSTRACT
Background:
Relebactam, previously known as MK-7655, is currently being tested in combination with imipenem as a class A and class C ß-lactamase inhibitor, including KPC from Klebsiella pneumoniae.Objective:
The objective of the current study was to evaluate the activity of imipenem/relebactam against gram-negative bacilli.Methods:
After applying exclusion and inclusion criteria, 72 articles with full texts that describe the prevalence of imipenem/relebactam resistance were chosen for the meta-analysis and systematic review. Articles published between January 2015 and February 2023 were surveyed. The systematic literature search was conducted in PubMed, Web of Science, Google Scholar, and Scopus.Results:
The pooled estimation of 282,621 sample isolates revealed that the prevalence rate of imipenem/relebactam resistance is roughly 14.6% (95% CI, 0.116%-0.182%).Conclusions:
The findings of this analysis show that imipenem/relebactam resistance is rare in the majority of developed countries. Given that relebactam has proven to restore the activity of imipenem against current clinical isolates, further research into imipenem/relebactam is necessary.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Risk_factors_studies
/
Systematic_reviews
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article